E
NKTR icon

Ergoteles’s Nektar Therapeutics NKTR Stock Holding History

Ergoteles’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,500
Closed -$21.6K – 566
2023
Q2 		$21.6K Buy
+2,500
New +$26.7K ﹤0.01% 985
2022
Q4 		– Sell
-1,279
Closed -$61K – 1737
2022
Q3 		$61K Buy
+1,279
New +$76.1K ﹤0.01% 1428
2022
Q2 		– Sell
-5,390
Closed -$436K – 1881
2022
Q1 		$436K Buy
5,390
+3,503
+186% +$518K 0.02% 711
2021
Q4 		$382K Sell
1,887
-3,500
-65% -$759K 0.01% 753
2021
Q3 		$1.45M Sell
5,387
-1,122
-17% -$270K 0.05% 309
2021
Q2 		$1.68M Buy
6,509
+4,669
+254% +$1.29M 0.04% 395
2021
Q1 		$552K Sell
1,840
-5,333
-74% -$1.66M 0.02% 470
2020
Q4 		$1.83M Buy
+7,173
New +$1.85M 0.06% 260

Other funds holding NKTR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Ergoteles's NKTR Position: Q3 2023 in Review

Ergoteles sold out of Nektar Therapeutics (NKTR) in Q3 2023, closing a stake of 2,500 shares — an estimated $21.6K sold.

Ergoteles first reported a position in NKTR in Q4 2020 and held it in 8 quarters. The position peaked at $1.83M in Q4 2020. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2023.

  • Ergoteles reported no remaining Nektar Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 2,500 Nektar Therapeutics shares in Q3 2023, an estimated $21.6K.
  • Ergoteles first reported a position in Nektar Therapeutics in Q4 2020 and held it in 8 quarters.
  • Ergoteles's Nektar Therapeutics position peaked at $1.83M in Q4 2020.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.